US5411748A - Prostate extract supplemented with zinc - Google Patents
Prostate extract supplemented with zinc Download PDFInfo
- Publication number
- US5411748A US5411748A US08/179,761 US17976194A US5411748A US 5411748 A US5411748 A US 5411748A US 17976194 A US17976194 A US 17976194A US 5411748 A US5411748 A US 5411748A
- Authority
- US
- United States
- Prior art keywords
- zinc
- fatty acids
- solvent
- group
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/52—Sperm; Prostate; Seminal fluid; Leydig cells of testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
Definitions
- This invention is directed to compositions and pharmaceutical preparations containing zinc chelated by essential fatty acids.
- Diabetes despite the availability of insulin treatment, remains an extremely serious disease, responsible for many deaths and substantial morbidity in the United States and other developed countries.
- insulin can regulate blood sugar levels in diabetics, the degree of control achieved with insulin is typically insufficient to prevent the occurrence of many sequelae from diabetes. These sequelae can include eye damage, often leading to blindness; circulatory problems; problems with wound healing; and other serious consequences. Therefore, improved treatments for diabetes are urgently required.
- Essential fatty acids include unsaturated fatty acids that are prostaglandin precursors, and administration of essential fatty acids is believed to be beneficial to diabetics (R. J. Illman et al., Atherosclerosis 59:313-321 (1986)).
- a composition of matter comprising crystalline zinc chelated unsaturated fatty acids meets this need by providing a convenient source of both zinc and essential fatty acids for treatment of diabetes and other conditions.
- the unsaturated fatty acids comprise essential fatty acids.
- the essential fatty acids can comprise fatty acids selected from the group consisting of prostaglandins and prostaglandin precursors.
- the essential fatty acids comprise at least one fatty acid selected from the group consisting of linoleic, linolenic, and arachidonic acids.
- Another aspect of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising, in a form administrable to a mammal:
- the essential fatty acids, the zinc chloride, and the protein hydrolysate are present in a ratio of about 10:1:5 in the pharmaceutical composition.
- the pharmaceutical composition can be in tablet form or capsule form; preferably, each tablet or capsule contains about 20 milligrams of zinc, with the essential fatty acids, the zinc chloride, and the protein hydrolysate being present in a ratio of about 10:1:5.
- Another aspect of the present invention is a method of treating diabetes comprising administering a pharmaceutical composition according to the present invention to a diabetic mammal in a quantity sufficient to reduce blood glucose concentration in the mammal.
- compositions of matter comprising crystalline zinc chelated unsaturated fatty acids, and pharmaceutical compositions comprising the crystalline fatty acids, zinc chloride, and a protein hydrolysate provide both zinc and fatty acids and are useful for treatment of diabetes and other conditions affecting zinc and essential fatty acid metabolism.
- One aspect of the present invention is crystalline zinc chelated unsaturated fatty acids, i.e., crystals in which negatively charged fatty acids are bound by positively charged zinc ions.
- the unsaturated fatty acids comprise essential fatty acids.
- the essential fatty acids preferably are selected from the group consisting of prostaglandins and prostaglandin precursors. These fatty acids can be obtained from animal prostates, such as cow, sheep, or goat by resuspending the prostates in a buffered aqueous solution, extracting the saturated fatty acids with a highly non-polar organic solvent such as petroleum ether or hexane, extracting unsaturated fatty acids with a more polar organic solvent such as ethyl acetate or chloroform, and then adding zinc chloride in a quantity sufficient to chelate the fatty acids present. Further details of the extraction procedure are given in Example 1, below.
- such essential fatty acids include at least one fatty acid selected from the group consisting of linoleic, linolenic, and arachidonic acid, which are unsaturated fatty acids that are precursors to prostaglandins.
- compositions contain: (1) essential fatty acids as disclosed above; (2) zinc chloride; (3) protein hydrolysate; and (4) at least one pharmaceutically acceptable excipient.
- the protein hydrolysate may be in the form of amino acids or incompletely hydrolyzed protein such as proteoses, peptones, or other partially hydrolyzed proteins, such as casein or albumin.
- compositions according to the present invention contain essential fatty acids, zinc chloride, and protein hydrolysate in a ratio of about 10:1:5 by weight.
- the pharmaceutical compositions can be packaged in tablet or capsule form by procedures well-known in the pharmaceutical art.
- each tablet or capsule contains about 200 mg of essential fatty acids, about 20 mg of zinc, and about 100 mg of protein hydrolysate, in addition to the pharmaceutically acceptable excipient or excipients.
- Suitable pharmaceutically acceptable excipients for tablets and capsules include inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.
- the coating of the capsules can be gelatin or a soluble polymer, as is well-understood in the art.
- the tablets or capsules are suitable for oral administration.
- the pharmaceutical compositions are useful for the treatment of diabetes, hypertension, impotence, and other diseases in which zinc or prostaglandin metabolism is impaired.
- diabetes can be treated by administering a pharmaceutical composition according to the present invention to a diabetic mammal in a quantity sufficient to reduce blood glucose concentration in the mammal.
- Typical doses for patients with diabetes or hypertension, stated as the quantity of zinc, are from about 80 mg to about 300 mg of zinc. These doses can be adjusted by one of ordinary skill in the art according to such factors as the weight, age, sex, and state of health of the patient, as well as according to the response to a particular dosage.
- Prostates from a cow or goat were obtained from a slaughterhouse, frozen at 70° C. and minced into small pieces.
- the sliced tissue was suspended in a 10-fold excess (w/v) of 5.0 mM Tris-HCl buffer, pH 8.0, homogenized with a homogenizer such as a Virtis-45 homogenizer (Virtis Co., Gardner, N.Y.), and centrifuged at 4° C. for 20 minutes at 3000 xg.
- the upper part of the fat was removed physically, and the supernatant was incubated at 37° C. for one hour.
- the saturated fatty acids were extracted with petroleum ether.
- the product at this stage was unsaturated fatty acids in an oil.
- Fifty-one rats were divided into three groups of 17 rats each. All of the rats were made diabetic by injection of streptozotocin. One week later, the rats were fed diets with defined quantities of zinc. The first group of 17 rats was fed a zinc-deficient diet with 1 ⁇ g Zn/g, the second group of 17 rats was fed a zinc-adequate diet (37.5 ⁇ g Zn/g), and the third group of 17 rats a zinc-excess diet (1 mg Zn/g). Twenty-five days later, the number of surviving rats was counted. Only 8 out of 17 rats in the zinc-deficient group survived while 11 out of 17 rats in the zinc-adequate group and 15 out of 17 rats in the zinc-excess group survived.
- Glucose concentration in the tissues of these rats is shown in Table 1. This data clearly indicates that an increase in dietary zinc enhances survival in diabetic rats and reduces the level of glucose present in the tissues of such rats. Because many diabetes complications are believed due to the presence of excess glucose in tissues, these results emphasize that an adequate zinc supply is important in preventing sequelae of diabetes.
- the present invention provides compositions that are a convenient source of both zinc and essential fatty acids as a dietary supplement or treatment for diabetes or other conditions. Because the metabolism of zinc and the metabolism of essential fatty acids, including prostaglandin precursors, are interlinked, the use of such compositions is more effective than is the use of either zinc or fatty acids alone in treating diabetes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
A composition of matter comprising zinc and an extract of animal prostatic tissue provides a convenient source of both fatty acids and zinc for dietary and therapeutic purposes. The pharmaceutical composition is useful for the treatment of diabetes. 05411748821 00000000000000000465034000000000000000000000000000000000000000000000000000000098
Description
This invention was made with Government support, namely, the facilities, equipment, and materials of the Department of Veterans' Affairs. The Government has certain rights in this invention.
This application is a continuation of application Ser. No. 07/964,879, filed Oct. 22, 1992, now abandoned.
This invention is directed to compositions and pharmaceutical preparations containing zinc chelated by essential fatty acids.
Diabetes, despite the availability of insulin treatment, remains an extremely serious disease, responsible for many deaths and substantial morbidity in the United States and other developed countries. Although insulin can regulate blood sugar levels in diabetics, the degree of control achieved with insulin is typically insufficient to prevent the occurrence of many sequelae from diabetes. These sequelae can include eye damage, often leading to blindness; circulatory problems; problems with wound healing; and other serious consequences. Therefore, improved treatments for diabetes are urgently required.
It is known that prostaglandins (PGs) bind zinc and regulate intestinal zinc transport (M. K. Song & N. F. Adham, "Role of Prostaglandin E2 in Zinc Absorption in the Rat," Am. J. Physiol. 234:E99-E105 (1978)) and that zinc influences prostaglandin synthesis activity in the small intestine and the vascular system of rats (M. K. Song & N. F. Adham, "Relationship Between Zinc and Prostaglandin Metabolisms in Plasma in Small Intestine of Rats," Am. J. Clin. Nutr. 41:1201-1209 (1985)). A relationship between zinc and the inhibition of glucose absorption is known (S. Southon et al., "Hexose Transport and Mucosal Morphology in the Small Intestine of the Zinc-Deficient Rat," Br. J. Nutr. 52:371-380 (1984)). Essential fatty acids include unsaturated fatty acids that are prostaglandin precursors, and administration of essential fatty acids is believed to be beneficial to diabetics (R. J. Illman et al., Atherosclerosis 59:313-321 (1986)).
However, because of the interaction between zinc metabolism and prostaglandin synthesis, administration of unsaturated fatty acids or essential fatty acids alone does not yield an optimum improvement in diabetes. Therefore, there is a need to provide an improved treatment of diabetes and other conditions in which zinc metabolism and fatty acid metabolism play roles by providing a convenient source of both zinc and essential fatty acids.
A composition of matter comprising crystalline zinc chelated unsaturated fatty acids meets this need by providing a convenient source of both zinc and essential fatty acids for treatment of diabetes and other conditions. Preferably, the unsaturated fatty acids comprise essential fatty acids. The essential fatty acids can comprise fatty acids selected from the group consisting of prostaglandins and prostaglandin precursors. Typically, the essential fatty acids comprise at least one fatty acid selected from the group consisting of linoleic, linolenic, and arachidonic acids.
Another aspect of the present invention is a pharmaceutical composition comprising, in a form administrable to a mammal:
(1) the crystalline zinc chelated unsaturated fatty acids of the present invention;
(2) zinc chloride;
(3) a protein hydrolysate; and
(4) at least one pharmaceutically acceptable excipient.
Preferably, the essential fatty acids, the zinc chloride, and the protein hydrolysate are present in a ratio of about 10:1:5 in the pharmaceutical composition. The pharmaceutical composition can be in tablet form or capsule form; preferably, each tablet or capsule contains about 20 milligrams of zinc, with the essential fatty acids, the zinc chloride, and the protein hydrolysate being present in a ratio of about 10:1:5.
Another aspect of the present invention is a method of treating diabetes comprising administering a pharmaceutical composition according to the present invention to a diabetic mammal in a quantity sufficient to reduce blood glucose concentration in the mammal.
I have discovered that a composition of matter comprising crystalline zinc chelated unsaturated fatty acids, and pharmaceutical compositions comprising the crystalline fatty acids, zinc chloride, and a protein hydrolysate provide both zinc and fatty acids and are useful for treatment of diabetes and other conditions affecting zinc and essential fatty acid metabolism.
I. CRYSTALLINE ZINC CHELATED UNSATURATED FATTY ACIDS
One aspect of the present invention is crystalline zinc chelated unsaturated fatty acids, i.e., crystals in which negatively charged fatty acids are bound by positively charged zinc ions.
Preferably, the unsaturated fatty acids comprise essential fatty acids. The essential fatty acids preferably are selected from the group consisting of prostaglandins and prostaglandin precursors. These fatty acids can be obtained from animal prostates, such as cow, sheep, or goat by resuspending the prostates in a buffered aqueous solution, extracting the saturated fatty acids with a highly non-polar organic solvent such as petroleum ether or hexane, extracting unsaturated fatty acids with a more polar organic solvent such as ethyl acetate or chloroform, and then adding zinc chloride in a quantity sufficient to chelate the fatty acids present. Further details of the extraction procedure are given in Example 1, below.
Typically, such essential fatty acids include at least one fatty acid selected from the group consisting of linoleic, linolenic, and arachidonic acid, which are unsaturated fatty acids that are precursors to prostaglandins.
II. PHARMACEUTICAL COMPOSITIONS
Another aspect of the present invention is pharmaceutical compositions. Pharmaceutical compositions according to the present invention contain: (1) essential fatty acids as disclosed above; (2) zinc chloride; (3) protein hydrolysate; and (4) at least one pharmaceutically acceptable excipient.
The protein hydrolysate may be in the form of amino acids or incompletely hydrolyzed protein such as proteoses, peptones, or other partially hydrolyzed proteins, such as casein or albumin.
Preferably, pharmaceutical compositions according to the present invention contain essential fatty acids, zinc chloride, and protein hydrolysate in a ratio of about 10:1:5 by weight. The pharmaceutical compositions can be packaged in tablet or capsule form by procedures well-known in the pharmaceutical art. Preferably, each tablet or capsule contains about 200 mg of essential fatty acids, about 20 mg of zinc, and about 100 mg of protein hydrolysate, in addition to the pharmaceutically acceptable excipient or excipients. Suitable pharmaceutically acceptable excipients for tablets and capsules include inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc. The coating of the capsules can be gelatin or a soluble polymer, as is well-understood in the art. The tablets or capsules are suitable for oral administration.
The pharmaceutical compositions are useful for the treatment of diabetes, hypertension, impotence, and other diseases in which zinc or prostaglandin metabolism is impaired. In particular, diabetes can be treated by administering a pharmaceutical composition according to the present invention to a diabetic mammal in a quantity sufficient to reduce blood glucose concentration in the mammal. Typical doses for patients with diabetes or hypertension, stated as the quantity of zinc, are from about 80 mg to about 300 mg of zinc. These doses can be adjusted by one of ordinary skill in the art according to such factors as the weight, age, sex, and state of health of the patient, as well as according to the response to a particular dosage.
Prostates from a cow or goat were obtained from a slaughterhouse, frozen at 70° C. and minced into small pieces. The sliced tissue was suspended in a 10-fold excess (w/v) of 5.0 mM Tris-HCl buffer, pH 8.0, homogenized with a homogenizer such as a Virtis-45 homogenizer (Virtis Co., Gardner, N.Y.), and centrifuged at 4° C. for 20 minutes at 3000 xg. The upper part of the fat was removed physically, and the supernatant was incubated at 37° C. for one hour. The saturated fatty acids were extracted with petroleum ether. The aqueous solution remaining, including the unsaturated fatty acids, was acidified to pH 3.0 with 0.2 N HCl, and the unsaturated fatty acid mixture including prostaglandins was extracted 2 to 3 times with one volume each time of ethyl acetate or chloroform. The ethyl acetate or chloroform extracts were combined. The unsaturated fatty acid solutions were freeze-dried to dryness or evaporated under vacuum. The product at this stage was unsaturated fatty acids in an oil. Then 200 mg of the extract was mixed with 40 mg zinc chloride and 100 mg protein hydrolysate to form a preparation of zinc chelated unsaturated fatty acids.
Fifty-one rats were divided into three groups of 17 rats each. All of the rats were made diabetic by injection of streptozotocin. One week later, the rats were fed diets with defined quantities of zinc. The first group of 17 rats was fed a zinc-deficient diet with 1 μg Zn/g, the second group of 17 rats was fed a zinc-adequate diet (37.5 μg Zn/g), and the third group of 17 rats a zinc-excess diet (1 mg Zn/g). Twenty-five days later, the number of surviving rats was counted. Only 8 out of 17 rats in the zinc-deficient group survived while 11 out of 17 rats in the zinc-adequate group and 15 out of 17 rats in the zinc-excess group survived. Glucose concentration in the tissues of these rats is shown in Table 1. This data clearly indicates that an increase in dietary zinc enhances survival in diabetic rats and reduces the level of glucose present in the tissues of such rats. Because many diabetes complications are believed due to the presence of excess glucose in tissues, these results emphasize that an adequate zinc supply is important in preventing sequelae of diabetes.
TABLE I ______________________________________ GLUCOSE CONCENTRATIONS IN TISSUES OF DIABETIC RATS FED DIETS WITH DIFFERENT CONCENTRATIONS OF ZINC Glucose Concentration Zinc-Deficient Zinc-Adequate Zinc-Excess Organ (1 μg Zn/g) (37.5 μg Zn/g) (1 mg Zn/g) ______________________________________ Heart.sup.a 5.54 1.17 0.95 Lung.sup.a 1.59 1.28 0.86 Liver.sup.a 8.39 5.20 5.54 Pancreas.sup.a 1.20 0.82 0.96 Spleen.sup.a 1.01 0.72 0.62 Kidney.sup.a 2.54 1.79 1.52 Muscle.sup.a 6.52 2.37 2.20 Small Intestine.sup.a 2.54 1.48 1.38 Colon.sup.a 3.18 3.05 2.81 Skin.sup.a 4.91 3.81 3.33 Plasma.sup.b 158 156 162 ______________________________________ .sup.a mg glucose/mg protein .sup.b mg glucose/mg plasma
The present invention provides compositions that are a convenient source of both zinc and essential fatty acids as a dietary supplement or treatment for diabetes or other conditions. Because the metabolism of zinc and the metabolism of essential fatty acids, including prostaglandin precursors, are interlinked, the use of such compositions is more effective than is the use of either zinc or fatty acids alone in treating diabetes.
Although the present invention has been described in considerable detail, with reference to certain preferred versions thereof, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description of the preferred versions contained herein.
Claims (7)
1. A composition of matter comprising zinc and extract of animal prostatic tissue, said tissue comprising a first group of molecules soluble in a first solvent which is a non-polar solvent having less polarity or the same polarity as petroleum ether or hexane, and also comprising a second group of molecules substantially insoluble in the first solvent, said extract being obtained by a process comprising:
(a) extracting the first group of molecules from the tissue in the first solvent;
(b) discarding the first solvent containing the first group of molecules;
(c) extracting said second group of molecules in a second solvent more polar than the first solvent; and
(d) removing the second solvent to create said extract.
2. A pharmaceutical composition comprising, in a form administrable to a mammal:
(a) a composition according to claim 1; and
(b) at least one pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 in tablet form.
4. The pharmaceutical composition of claim 3 wherein each tablet contains about 20 milligrams of zinc.
5. The pharmaceutical composition of claim 2 in capsule form.
6. The pharmaceutical composition of claim 2 wherein said composition contains from about 20 milligrams of zinc to about 300 milligrams of zinc.
7. A method of treating diabetes in a diabetic mammal comprising administering the composition of claim 2 to said diabetic mammal in a quantity sufficient to reduce blood glucose concentration in the mammal.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/179,761 US5411748A (en) | 1992-10-22 | 1994-01-07 | Prostate extract supplemented with zinc |
EP94911634A EP0785791B1 (en) | 1994-01-07 | 1994-03-17 | Prostate extract supplemented with zinc |
PCT/US1994/002909 WO1995024911A1 (en) | 1994-01-07 | 1994-03-17 | Prostate extract supplemented with zinc |
US08/718,299 US5997908A (en) | 1992-10-22 | 1994-03-17 | Prostate extract supplemented with zinc |
CA002185678A CA2185678A1 (en) | 1992-10-22 | 1994-03-17 | Prostate extract supplemented with zinc |
AU64108/94A AU6410894A (en) | 1994-01-07 | 1994-03-17 | Prostate extract supplemented with zinc |
DE69421416T DE69421416T2 (en) | 1994-01-07 | 1994-03-17 | WITH ZINC SUPPLEMENTED PROSTATE EXTRACT |
KR1019950700200A KR100304312B1 (en) | 1994-01-07 | 1994-03-17 | Zinc Supplemented Prostate Extract |
TW083109123A TW358029B (en) | 1992-10-22 | 1994-10-03 | A pharmaceutical composition containing crystalline chelate of zinc with the extract of bovine prostatic tissue for use in the treatment of diabetes mellitus |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96487992A | 1992-10-22 | 1992-10-22 | |
US08/179,761 US5411748A (en) | 1992-10-22 | 1994-01-07 | Prostate extract supplemented with zinc |
CA002185678A CA2185678A1 (en) | 1992-10-22 | 1994-03-17 | Prostate extract supplemented with zinc |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US96487992A Continuation | 1992-10-22 | 1992-10-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/718,299 Continuation-In-Part US5997908A (en) | 1992-10-22 | 1994-03-17 | Prostate extract supplemented with zinc |
Publications (1)
Publication Number | Publication Date |
---|---|
US5411748A true US5411748A (en) | 1995-05-02 |
Family
ID=25678681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/179,761 Expired - Lifetime US5411748A (en) | 1992-10-22 | 1994-01-07 | Prostate extract supplemented with zinc |
Country Status (4)
Country | Link |
---|---|
US (1) | US5411748A (en) |
EP (1) | EP0785791B1 (en) |
KR (1) | KR100304312B1 (en) |
WO (1) | WO1995024911A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543146A (en) * | 1995-01-20 | 1996-08-06 | Prostahelp, Inc. | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland |
US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
US6686392B1 (en) | 2002-10-01 | 2004-02-03 | Elena Avram | Lipidic zinc compounds and use for treatment of prostatic hypertrophy |
US20040086563A1 (en) * | 1997-03-14 | 2004-05-06 | Domenico Fanara | Pharmaceutical compositions for the controlled release of active substances |
US20040185125A1 (en) * | 2003-01-31 | 2004-09-23 | Song Moon K. | Compositions and methods for treating obesity |
US20090004291A1 (en) * | 2007-03-02 | 2009-01-01 | Song Moon K | Compositions and methods for treating alzheimer's disease and dementia |
EP2040756A1 (en) * | 2006-07-13 | 2009-04-01 | Mazence Inc. | Composition containing metal-acidic amino acid chelate accelerating absorption of metal |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000001396A1 (en) * | 1998-07-01 | 2000-01-13 | Debiopharm S.A. | Pharmaceutical composition for treating sexual dysfunction |
JP2001220348A (en) * | 1999-11-30 | 2001-08-14 | Japan Science & Technology Corp | Hypoglycemic comprising zinc (ii) organic complex |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302447A (en) | 1978-01-23 | 1981-11-24 | Efamol Limited | Pharmaceutical and dietary composition |
SU1740004A1 (en) | 1989-06-19 | 1992-06-15 | 1-Й Ленинградский Медицинский Институт Им.Акад.И.П.Павлова | Method for treating chronic prostatitis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE11014T1 (en) * | 1981-07-14 | 1985-01-15 | Efamol Limited | PHARMACEUTICAL AND DIETETIC COMPOSITION TO INCREASE SERIES L-PG PRODUCTION. |
GB8425006D0 (en) * | 1984-10-03 | 1984-11-07 | Efamol Ltd | Composition of copper/fatty acids |
RU1417244C (en) * | 1986-02-03 | 1994-06-30 | Хавинсон Владимир Хацкелевич | Method of preparing of substance recovering prostate gland function |
EP0372676A1 (en) * | 1988-12-08 | 1990-06-13 | Spyros Carantinos | Therapeutic preparation and method |
WO1993000894A1 (en) * | 1991-07-03 | 1993-01-21 | Scott Nathan E | Prostaglandin e2 treatment of impotence |
-
1994
- 1994-01-07 US US08/179,761 patent/US5411748A/en not_active Expired - Lifetime
- 1994-03-17 EP EP94911634A patent/EP0785791B1/en not_active Expired - Lifetime
- 1994-03-17 WO PCT/US1994/002909 patent/WO1995024911A1/en active IP Right Grant
- 1994-03-17 KR KR1019950700200A patent/KR100304312B1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4302447A (en) | 1978-01-23 | 1981-11-24 | Efamol Limited | Pharmaceutical and dietary composition |
SU1740004A1 (en) | 1989-06-19 | 1992-06-15 | 1-Й Ленинградский Медицинский Институт Им.Акад.И.П.Павлова | Method for treating chronic prostatitis |
Non-Patent Citations (46)
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543146A (en) * | 1995-01-20 | 1996-08-06 | Prostahelp, Inc. | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland |
US20040086563A1 (en) * | 1997-03-14 | 2004-05-06 | Domenico Fanara | Pharmaceutical compositions for the controlled release of active substances |
US7083807B2 (en) | 1997-03-14 | 2006-08-01 | Ucb, S.A. | Pharmaceutical compositions for the controlled release of active substances |
US20030072731A1 (en) * | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing starch or dextrin |
US6686392B1 (en) | 2002-10-01 | 2004-02-03 | Elena Avram | Lipidic zinc compounds and use for treatment of prostatic hypertrophy |
US20040185125A1 (en) * | 2003-01-31 | 2004-09-23 | Song Moon K. | Compositions and methods for treating obesity |
US7144865B2 (en) | 2003-01-31 | 2006-12-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for treating obesity |
EP2040756A1 (en) * | 2006-07-13 | 2009-04-01 | Mazence Inc. | Composition containing metal-acidic amino acid chelate accelerating absorption of metal |
EP2040756A4 (en) * | 2006-07-13 | 2013-01-09 | Mazence Inc | Composition containing metal-acidic amino acid chelate accelerating absorption of metal |
US20090004291A1 (en) * | 2007-03-02 | 2009-01-01 | Song Moon K | Compositions and methods for treating alzheimer's disease and dementia |
US10058520B2 (en) | 2007-03-02 | 2018-08-28 | Department Of Veterans Affairs | Compositions and methods for treating alzheimer's disease and dementia |
Also Published As
Publication number | Publication date |
---|---|
EP0785791A4 (en) | 1997-07-30 |
KR100304312B1 (en) | 2001-11-22 |
KR960700064A (en) | 1996-01-19 |
EP0785791A1 (en) | 1997-07-30 |
WO1995024911A1 (en) | 1995-09-21 |
EP0785791B1 (en) | 1999-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Peters | Croonian lecture-lethal synthesis | |
AU664511B2 (en) | Method of promoting nitrogen retention in humans | |
Bertaccini | Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat | |
US4590184A (en) | Antiosteoporotic pharmaceutical composition containing 24,25-dihydroxycholecalciferol as an active ingredient | |
US4432975A (en) | Process for introducing vitamin B-12 into the bloodstream | |
KR950009094B1 (en) | Pharmaceutical compositions containing pyridoxine derivatives for use in the prevention and treatment of hyperlipemia and atherosclerosis | |
US4438144A (en) | Amino acid preparation and therapy for treatment of stress and injury | |
US5230996A (en) | Use of ascorbate and tranexamic acid solution for organ and blood vessel treatment prior to transplantation | |
US5411748A (en) | Prostate extract supplemented with zinc | |
JPH06500109A (en) | Products containing growth factors and glutamine and the use of growth factors for the treatment of intestinal mucosa | |
HU201671B (en) | Process for producing active ingredient mixture and pharmaceutical compositions comprising unsaturated fatty acids necessary for the synthesis of prostaglandins and hydroxy fatty acids in biological systems | |
US6165515A (en) | Method for treatment of osteoporosis | |
CZ382799A3 (en) | Use of zinc hyaluronate against peptic ulcers | |
JPH01287040A (en) | Stimulation of immune system | |
KR102054942B1 (en) | Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility | |
Daft et al. | Sulfonamides and vitamin deficiencies | |
US4291030A (en) | Method of lowering blood cholesterol | |
JPH04312527A (en) | Method of treating hepatic inssuficiency and liver disease | |
US5997908A (en) | Prostate extract supplemented with zinc | |
US4775665A (en) | Method and composition for treating neurological disorders and aging | |
KR100312245B1 (en) | Zinc Tablets Chelated by Essential Fatty Acids | |
EP0057209A1 (en) | Novel amino acid preparation and therapy for treatment of stress and injury | |
WO1991019488A1 (en) | REDUCTION OF CARDIOVASCULAR VESSEL OCCLUSIONS WITH ASCORBATE AND LIPOPROTEIN (a) BINDING INHIBITORS | |
US4686225A (en) | Vinpocetine for pulmonary hemorrhage and edema | |
Bounous | Elemental diets in the prophylaxis and therapy for intestinal lesions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |